A Phase II trial find out the effectiveness and safety of durvalumab combined with olaparib compared to durvalumab alone, in treating patients with metastatic non-small cell lung cancer who have not had worsening of their cancer after treatment with durvalumab and chemotherapy.

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: c854c04adb615c458049f976404ba28030149c8b
First added on: Mar 21, 2025